Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Chronic inflammatory demyelinating polyradiculoneuropathy
ADR ID BADD_A05515
ADR Hierarchy
17      Nervous system disorders
17.09      Peripheral neuropathies
17.09.04      Chronic polyneuropathies
17.09.04.004      Chronic inflammatory demyelinating polyradiculoneuropathy
10      Immune system disorders
10.04      Autoimmune disorders
10.04.10      Nervous system autoimmune disorders
10.04.10.004      Chronic inflammatory demyelinating polyradiculoneuropathy
Description A slowly progressive autoimmune demyelinating disease of peripheral nerves and nerve roots. Clinical manifestations include weakness and sensory loss in the extremities and enlargement of peripheral nerves. The course may be relapsing-remitting or demonstrate a step-wise progression. Protein is usually elevated in the spinal fluid and cranial nerves are typically spared. GUILLAIN-BARRE SYNDROME features a relatively rapid progression of disease which distinguishes it from this condition. (Adams et al., Principles of Neurology, 6th ed, p1337) [MeSH]
MedDRA Code 10057645
MeSH ID D020277
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Chronic inflammatory demyelinating polyradiculoneuropathy | CIDP | Chronic inflammatory demyelinating polyneuropathy | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Polyneuropathy, Inflammatory Demyelinating, Chronic | Inflammatory Polyradiculopathy, Chronic | Chronic Inflammatory Polyradiculopathies | Chronic Inflammatory Polyradiculopathy | Inflammatory Polyradiculopathies, Chronic | Polyradiculopathies, Chronic Inflammatory | Polyradiculopathy, Chronic Inflammatory | Polyradiculoneuropathy, Chronic Inflammatory | Chronic Inflammatory Polyradiculoneuropathy | Chronic Inflammatory Polyradiculoneuropathies | Polyradiculoneuropathies, Chronic Inflammatory | Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00064Alemtuzumab--
BADD_D00511Clozapine0.001834%
BADD_D00774Entecavir0.003269%
BADD_D00798Eribulin0.000112%
BADD_D01157Infliximab--
BADD_D01253Lenalidomide0.000241%
BADD_D01275Levofloxacin0.000042%
BADD_D01798Pomalidomide0.000241%
BADD_D01831Prednisolone0.000122%
BADD_D01954Rivaroxaban--
BADD_D02392Zoledronic acid0.005726%
The 1th Page    1    Total 1 Pages